Big Pharma Wants To Turn Toad Venom Into The Next Blockbuster Drug
The Wall Street Journal reports major drugmakers are funding synthetic 5-MeO-DMT, derived from Colorado River toad venom, seeking FDA approval for depression or other mental health uses. The compound is illegal in the US and can cause intense adverse experiences. Eli Lilly expanded into psychedelics by acquiring AtaiBeckley for $2.8 billion, gaining a breakthrough-designated analog. AtaiBeckley shares rose 253% since Jan 2025.
How this was made
.jpg&w=3840&q=75)
The 30-second read
Why it matters
The actionable element is the reported Lilly acquisition of AtaiBeckley for $2.8B and the claim that the acquired analog has FDA breakthrough designation, which can shift perceived development probability. However, the article also stresses safety concerns and the drug’s US illegality, which can slow or complicate clinical translation and approval timelines.
Market read
Deal headline plus breakthrough designation can drive biotech repricing, but the lack of new trial data and the highlighted safety and legal uncertainties reduce near-term conviction.
What to watch
No new clinical efficacy or safety trial results are provided; market may discount the FDA breakthrough designation until robust data and real-world tolerability are demonstrated.
Background
The piece frames 5-MeO-DMT (bufo) as a naturally derived psychedelic compound from toad venom, with pharma interest in a synthetic, potentially shorter-session clinical format.
Ticker impact
Article says Eli Lilly expanded into psychedelics and acquired AtaiBeckley for $2.8B, giving access to a breakthrough-designated analog.
Near-term sentiment could be supportive for LLY due to deal headline, but fundamental impact depends on clinical/regulatory progress.
The text provides a specific deal size and a claimed FDA breakthrough designation for the acquired analog, which can improve perceived development optionality, though no new trial data or approval is disclosed.
AtaiBeckley is described as the target of Lilly’s $2.8B acquisition, with its 5-MeO-DMT analog said to have FDA breakthrough designation.
If the market treats the report as credible, ATAI could see deal-related repricing, but the article does not provide deal terms beyond the headline value.
The article states the acquisition and highlights FDA breakthrough designation for the relevant analog, but it lacks additional deal mechanics (consideration structure, timing, conditions) and does not confirm a definitive agreement.
Market effects
Reinforces capital rotation into psychedelic therapeutics and may raise attention on 5-MeO-DMT safety, regulatory pathway, and breakthrough-designated analogs.
Primarily US-focused regulatory and biotech sentiment; could influence US-listed psychedelic peers via read-through on deal appetite.
If FDA breakthrough pathways prove workable, it can attract global pharma investment into psychedelic-derived compounds and synthetic analog development.
Counterpoint
The article emphasizes legality and potential severe adverse outcomes, so the deal may be more speculative than the breakthrough label implies.
Key entities
- companyEli Lilly
Reported to have acquired AtaiBeckley for $2.8B to access a 5-MeO-DMT-related analog with FDA breakthrough designation.
- companyAtaiBeckley
Reported target of Lilly’s $2.8B acquisition; its promoted analog is described as having FDA breakthrough designation.
- regulatorFDA
Referenced via breakthrough designation and panel/approval context for psychedelic-related therapeutics.
- government_officialRobert Kennedy Jr.
Quoted discussing rapid-onset advantages and a goal to make clinical-setting delivery happen within 12 months.
